Uroplasty, Inc. (Minneapolis) has announced that two additional private insurance payers will cover posterior tibial nerve stimulation (PTNS) using its Urgent PC Neuromodulation System for the treatment of overactive bladder and associated symptoms.
Uroplasty, Inc. (Minneapolis) has announced that two additional private insurance payers will cover posterior tibial nerve stimulation (PTNS) using its Urgent PC Neuromodulation System for the treatment of overactive bladder and associated symptoms.
Effective Aug. 1, 2011, Health Care Service Corp. will begin covering and paying for PTNS therapy for patients in Texas, Illinois, New Mexico, and Oklahoma. Additionally, effective May 18, 2011, BlueCross BlueShield of Nebraska initiated coverage of PTNS treatments.
"We have now secured coverage from three of the four largest private payers in the United States," said David Kaysen, president and CEO of Uroplasty. "We estimate that in total, the Medicare and private-pay carriers that today provide coverage for PTNS treatments represent approximately 115 million lives."
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.